Related Experiment Video
Updated: May 14, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Multiple sclerosis: individualized disease susceptibility and therapy response.
Vera Pravica1, Milos Markovic, Maja Cupic
1Institute of Microbiology & Immunology, School of Medicine, University of Belgrade, Belgrade, Serbia. pravica@med.bg.ac.rs
Biomarkers in Medicine
|February 8, 2013
Summary
Personalized medicine for multiple sclerosis (MS) requires tailoring treatments. Genetic and non-genetic biomarkers can help predict disease course and therapy response for individual patients.
Area of Science:
- Neurology
- Immunology
- Genetics
Background:
- Multiple sclerosis (MS) is a complex neurological disorder with significant heterogeneity.
- Variability in genetic, pathological, and clinical factors influences patient responses to therapies.
- Personalized care is essential for optimizing treatment outcomes in MS.
Purpose of the Study:
- To review the potential of biomarkers in personalizing multiple sclerosis management.
- To explore how genetic and non-genetic biomarkers can aid in diagnosis and prognosis.
- To assess the role of biomarkers in predicting therapeutic responses in MS patients.
Main Methods:
- Literature review and analysis of current research on biomarkers in multiple sclerosis.
- Examination of genetic factors, pathological markers, and clinical data.
- Evaluation of decision-making algorithms for personalized MS care.
Main Results:
- Biomarkers show promise in stratifying MS patients based on disease characteristics.
- Genetic and non-genetic markers can improve diagnostic accuracy and disease course prediction.
- Predictive models using biomarkers can guide the selection of disease-modifying therapies.
Conclusions:
- Biomarkers are crucial for advancing personalized medicine in multiple sclerosis.
- Integrating biomarker data into clinical practice can optimize treatment strategies.
- Further research is needed to fully leverage biomarkers for individual MS patient management.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...